Thromboangiitis obliterans: Aggressive angioplasty provides a potential solution (randomized pilot study)

Endovascular treatment for thromboangiitis obliterans (Buerger’s disease)

This is a protocol for a Cochrane Review (intervention). The objectives are as follows:

To assess the effectiveness and safety of endovascular treatment for thromboangiitis obliterans (Buerger’s disease).

A SYSTEMATIC REVIEW AND META-ANALYSIS OF EARLY AND LATE OUTCOMES AFTER ENDOVASCULAR ANGIOPLASTY AMONG PATIENTS WITH THROMBOANGIITIS OBLITERANS AND CHRONIC LIMB ISCHEMIA

INTRODUCTION

There is still no consensus on optimal treatment among patients with Thromboangiitis obliterans (TO) and chronic limb ischemia. The present study aims to summarize results on endovascular treatment of such patients.

METHODS

This is a meta-analysis. The following databases were utilized: Pubmed, Scopus and Cochrane Library. Eligible studies were published up to December 2021 and they evaluated endovascular angioplasty among patients with TO and chronic limb ischemia. Early (mortality and technical success) and late (primary/secondary patency and limb salvage) outcomes were evaluated. StatsDirect® was used for statistical analysis.

RESULTS

Overall, 15 eligible studies were included (11 studies only endovascular, 4 studies both endovascular and open repair). Among 601 patients, 402 endovascular procedures (416 limbs) were recorded (angioplasty plus stenting in 7.2% of cases and plus thrombolysis in 3.7% of cases). Regarding clinical presentation, 7.9% of patients had intermittent claudication (stages II/III) and 92.1% critical ischemia (stages IV-VI). The majority of cases had lesions below the knee, whereas there were 5 cases with upper extremity lesions. Pooled technical success was 86% (81.1-90.3) and in-hospital mortality null. Other complications included: 1.9% perforations, 2.2% wound complications, 0.2% distal embolism. Primary patency reached 65.7% (52.7-77.6) at 12 months and 50.7% (23.3-77.9) at 36 months. Secondary patency reached 76.2% (57.5-90.8) at 12 months and 64.5% (32.3-90.6) at 36 months. Limb salvage reached 94.1% (90.7-96.7) at 12 months and 89.1% (80.6-95.4) at 36 months.

CONCLUSIONS

Endovascular angioplasty in patients with TO and chronic limb ischemia is associated with optimal safety and low complication rates. Technical success and late outcomes are acceptable.

miR-100 alleviates the inflammatory damage and apoptosis of H2O2-induced human umbilical vein endothelial cells via inactivation of Notch signaling by targeting MMP9

OBJECTIVE

Thromboangiitis obliterans is a nonatherosclerotic segmental inflammatory disease, and miR-100 plays an anti-inflammatory role in chronic inflammation. Therefore, we hypothesized that miR-100 might alleviate the inflammatory damage and apoptosis of H₂O₂-induced ECV304 cells and aimed to investigate the relationship between miR-100 and thromboangiitis obliterans and the related molecular mechanism.

METHODS

Cell counting kit-8 was used to detect cell viability, and the expression of inflammatory factors and oxidative stress was measured by ELISA. TUNEL assay was used to detect the apoptosis of human umbilical vein endothelial cells after induction by H₂O₂. Furthermore, the interaction between miR-100 and matrix metalloproteinase-9 was verified by dual-luciferase assay. Quantitative reverse transcription polymerase chain reaction and western blot were used to detect the expression of the adhesion factors, apoptosis-related proteins and Notch pathway-related protein.

RESULTS

The results revealed that miR-100 was decreased in H₂O₂-induced human umbilical vein endothelial cells. Overexpression of miR-100 attenuated inflammatory response and cell apoptosis in H₂O₂-induced human umbilical vein endothelial cells. The overexpression of miR-100 inhibited matrix metalloproteinase-9 expression in H₂O₂-induced human umbilical vein endothelial cells. miR-100 inhibited H₂O₂-induced human umbilical vein endothelial cell inflammation, oxidative stress, and cell apoptosis via inactivation of Notch signaling by targeting matrix metalloproteinase.

CONCLUSIONS

Our study demonstrated that miR-100 reduced the inflammatory damage and apoptosis of H₂O₂-induced human umbilical vein endothelial cells via inactivation of Notch signaling by targeting matrix metalloproteinase. These findings suggested that miR-100 might be a novel therapeutic target for the prevention of thromboangiitis obliterans.